TFA Therapeutics, Inc. (RAJAF): Operating Income

Annual figures by period end, from SEC filings.

-$141.1K
Year ended 2025-12-31
$227.8K2021-12-31: -$119.4K2022-12-31: -$415.1K2023-12-31: $227.8K2024-12-31: -$183.9K2025-12-31: -$141.1K-$141.1K
2021-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$141.1Kn/m2026-05-15, From 2025-01-01
2024-12-31-$183.9Kn/m2026-05-15, From 2024-01-01
2023-12-31$227.8Kn/m2026-05-15, From 2023-01-01
2022-12-31-$415.1Kn/m2025-09-23, From 2022-01-01
2021-12-31-$119.4Kn/a2025-09-23, From 2021-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Medicinal Chemicals & Botanical Products), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
TFA Therapeutics, Inc. (RAJAF)2025-12-31-$141.1Kn/m
Adia Med, Inc. (ADIA)2025-12-31-$366.5Kn/m
China Foods Holdings Ltd. (CFOO)2025-12-31-$398.9Kn/m
Nutra Pharma Corp (NPHC)2025-12-31-$1.46Mn/m
Functional Brands Inc. (MEHA)2025-12-31-$1.40Mn/m
Bon Natural Life Ltd (BON)2025-09-30-$1.62Mn/m
Charlie's Holdings, Inc. (CHUC)2025-12-31-$2.17Mn/m
Cyanotech Corp (CYAN)2025-03-31-$2.51Mn/m
Synergy CHC Corp. (SNYRQ)2025-12-31-$8.46Mn/m

Compare RAJAF, ADIA, CFOO, NPHC side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗